5200 ILLUMINA WAY, SAN DIEGO, CA
Illumina Completes $300 Million Public Offering of 4.950% Notes Due 2029
Illumina Enters $1 Billion Credit Agreement for Revolving Credit Facility
Illumina Enters Underwriting Agreement for $300 Million Notes Offering
Notice of Pendency of the Action, Proposed Dismissal of the Action, and Dismissal Hearing
Financial Results, Press Release
Daniel M. Skovronsky, MD, PhD, appointed to the Board of Directors
Illumina, Inc. Annual Meeting Results; Board Elections and Auditor Ratification
Financial Results, Other Events
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus Filed Pursuant to Rule 424(b)(2)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Definitive Additional Information Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Free Writing Prospectus
Specialized Disclosure Report
Definitive Revised Proxy Statement